Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates

Cellular & Molecular Immunology volume 15, pages 421–427 (2018)Cite this article

Abstract

Malignant cells upregulate distinct energy metabolism programs that support their proliferation, migration, and adaptation to the stressful tumor microenvironment (TME). Additionally, this exaggerated metabolic activity allows cancer cells to hijack essential nutrients and outcompete neighboring infiltrating immune cells, thereby impairing antitumor immunity. During recent years, there has been great interest in the field to understand the tumor-induced energy metabolism signals that regulate the function of immune cells in individuals with cancer. Accordingly, it is now well accepted that uncovering the mechanisms that instruct the metabolic behavior of cancer cells and tumor-associated immune cells is an indispensable strategy for the development of new approaches to overcome immune suppression in tumors. Thus, in this minireview, we briefly discuss the interaction between particular metabolic signaling pathways and immunosuppressive activity in different subsets of myeloid cells within the TME. Additionally, we illustrate potential central mechanisms controlling the metabolic reprogramming of myeloid cells in response to tumor-derived factors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: STAT3/STAT5 and AMPK mediate the metabolic reprogramming of MDSCs to FAO within the TME.
Fig. 2: Malignant cells are characterized by metabolic alterations that correspond to their pathological proliferation, differentiation, and metastasis.

Similar content being viewed by others

References

  1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297–308 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351–359 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559–563 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Calcinotto, A. et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 72, 2746–2756 (2012).

    Article  CAS  PubMed  Google Scholar 

  7. Husain, Z., Huang, Y., Seth, P. & Sukhatme, V. P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191, 1486–1495 (2013).

    Article  CAS  PubMed  Google Scholar 

  8. Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618–631 (2008).

    Article  CAS  PubMed  Google Scholar 

  9. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Biswas, S. K. Metabolic reprogramming of immune cells in cancer progression. Immunity 43, 435–449 (2015).

    Article  CAS  PubMed  Google Scholar 

  13. Biswas, S. K. & Mantovani, A. Orchestration of metabolism by macrophages. Cell Metab. 15, 432–437 (2012).

    Article  CAS  PubMed  Google Scholar 

  14. Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Metabolic instruction of immunity. Cell 169, 570–586 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mills, E. L., Kelly, B. & O’Neill, L. A. J. Mitochondria are the powerhouses of immunity. Nat. Immunol. 18, 488–498 (2017).

    Article  CAS  PubMed  Google Scholar 

  16. Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 (1927).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Moreira, J. D. et al. The redox status of cancer cells supports mechanisms behind the Warburg effect. Metabolites 6, pii: E33 (2016).

    Article  CAS  Google Scholar 

  18. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).

    Article  CAS  Google Scholar 

  19. Keibler, M. A. et al. Metabolic requirements for cancer cell proliferation. Cancer Metab. 4, 16 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  20. Al-Khami, A. A., Rodriguez, P. C. & Ochoa, A. C. Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer. Oncoimmunology 5, e1200771 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Al-Khami, A. A., Rodriguez, P. C. & Ochoa, A. C. Energy metabolic pathways control the fate and function of myeloid immune cells. J. Leukoc. Biol. 102, 369–380 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Biswas, S. K., Allavena, P. & Mantovani, A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 35, 585–600 (2013).

    Article  CAS  PubMed  Google Scholar 

  23. Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).

    Article  CAS  PubMed  Google Scholar 

  24. Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496, 238–242 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rodriguez-Prados, J. C. et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J. Immunol. 185, 605–614 (2010).

    Article  CAS  PubMed  Google Scholar 

  26. Biswas, S. K., Sica, A. & Lewis, C. E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 180, 2011–2017 (2008).

    Article  CAS  PubMed  Google Scholar 

  27. Burke, B. et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am. J. Pathol. 163, 1233–1243 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Everts, B. et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 120, 1422–1431 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Vats, D. et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell. Metab. 4, 13–24 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Huang, S. C. et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity 45, 817–830 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274–288 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ginhoux, F. & Guilliams, M. Tissue-resident macrophage ontogeny and homeostasis. Immunity 44, 439–449 (2016).

    Article  CAS  PubMed  Google Scholar 

  34. Zhu, Y. et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47, 597 (2017).

    Article  CAS  PubMed  Google Scholar 

  35. Pearce, E. J. & Everts, B. Dendritic cell metabolism. Nat. Rev. Immunol. 15, 18–29 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Everts, B. et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation. Nat. Immunol. 15, 323–332 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Jantsch, J. et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J. Immunol. 180, 4697–4705 (2008).

    Article  CAS  PubMed  Google Scholar 

  38. Scarlett, U. K. et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209, 495–506 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013–2021 (2006).

    Article  CAS  PubMed  Google Scholar 

  40. Novitskiy, S. V. et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822–1831 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880–886 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cubillos-Ruiz, J. R., Bettigole, S. E. & Glimcher, L. H. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell 168, 692–706 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Jun, H. S., Weinstein, D. A., Lee, Y. M., Mansfield, B. C. & Chou, J. Y. Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. Blood 123, 2843–2853 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Rodriguez-Espinosa, O., Rojas-Espinosa, O., Moreno-Altamirano, M. M., Lopez-Villegas, E. O. & Sanchez-Garcia, F. J. Metabolic requirements for neutrophil extracellular traps formation. Immunology 145, 213–224 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519–531 (2011).

    Article  CAS  PubMed  Google Scholar 

  46. Singhal, S. et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30, 120–135 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Condamine, T. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 1, pii: aaf8943 (2016).

    Article  Google Scholar 

  48. Goffaux, G., Hammami, I. & Jolicoeur, M. A dynamic metabolic flux analysis of myeloid-derived suppressor cells confirms immunosuppression-related metabolic plasticity. Sci. Rep. 7, 9850 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  49. Jian, S. L. et al. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death Dis. 8, e2779 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Liu, G. et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis. Cancer Res. 74, 727–737 (2014).

    Article  CAS  PubMed  Google Scholar 

  51. Lu Y. et al. Glucocorticoid receptor promotes the function of myeloid-derived suppressor cells by suppressing HIF1alpha-dependent glycolysis. Cell. Mol. Immunol. (2017). https://doi.org/10.1038/cmi.2017.5.

    Article  CAS  Google Scholar 

  52. Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Nomura, D. K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49–61 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Currie, E., Schulze, A., Zechner, R., Walther, T. C. & Farese, R. V. Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153–161 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gao, F. et al. Radiation-driven lipid accumulation and dendritic cell dysfunction in cancer. Sci. Rep. 5, 9613 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527–1538 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hossain, F. et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 3, 1236–1247 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Condamine, T. et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J. Clin. Invest. 124, 2626–2639 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Al-Khami, A. A. et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology 6, e1344804 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  60. Hammami, I. et al. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol. 13, 18 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. O’Neill, L. A. & Pearce, E. J. Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213, 15–23 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. O’Neill, L. A. & Hardie, D. G. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493, 346–355 (2013).

    Article  PubMed  CAS  Google Scholar 

  63. Galic, S. et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 121, 4903–4915 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Egan, D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456–461 (2011).

    Article  CAS  PubMed  Google Scholar 

  65. Toyama, E. Q. et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351, 275–281 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Rabinovitch, R. C. et al. AMPK maintains cellular metabolic homeostasis through regulation of mitochondrial reactive oxygen species. Cell Rep. 21, 1–9 (2017).

    Article  CAS  PubMed  Google Scholar 

  67. Krawczyk, C. M. et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115, 4742–4749 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Trikha, P. et al. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology 5, e1214787 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Kim, S. H. et al. Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma. J. Invest. Dermatol. 137, 1740–1748 (2017).

    Article  CAS  PubMed  Google Scholar 

  70. Rong, Y. et al. Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. Sci. Rep. 6, 23824 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Steinberg, G. R. & Schertzer, J. D. AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: implications for diabetes and cardiovascular disease. Immunol. Cell. Biol. 92, 340–345 (2014).

    Article  CAS  PubMed  Google Scholar 

  72. Sag, D., Carling, D., Stout, R. D. & Suttles, J. Adenosine 5’-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181, 8633–8641 (2008).

    Article  CAS  PubMed  Google Scholar 

  73. Park, S. Y. et al. SIRT1/adenosine monophosphate-activated protein kinase alpha signaling enhances macrophage polarization to an anti-inflammatory phenotype in rheumatoid arthritis. Front. Immunol. 8, 1135 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Rodriguez, P. C. et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202, 931–939 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P. & Kalinski, P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71, 7463–7470 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Mao, Y. et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 73, 3877–3887 (2013).

    Article  CAS  PubMed  Google Scholar 

  78. Mao, Y. et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res. 20, 4096–4106 (2014).

    Article  CAS  PubMed  Google Scholar 

  79. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).

    Article  CAS  PubMed  Google Scholar 

  80. Hsu, Y. L. et al. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget 7, 27584–27598 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  81. Munn, D. H. & Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34, 137–143 (2013).

    Article  CAS  PubMed  Google Scholar 

  82. Rath, M., Muller, I., Kropf, P., Closs, E. I. & Munder, M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front. Immunol. 5, 532 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Modolell, M., Corraliza, I. M., Link, F., Soler, G. & Eichmann, K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25, 1101–1104 (1995).

    Article  CAS  PubMed  Google Scholar 

  84. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15, 323–350 (1997).

    Article  CAS  PubMed  Google Scholar 

  85. Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2, 907–916 (2001).

    Article  CAS  PubMed  Google Scholar 

  86. Albina, J. E. & Reichner, J. S. Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer Metastasis Rev. 17, 39–53 (1998).

    Article  CAS  PubMed  Google Scholar 

  87. Stuehr, D. J. & Nathan, C. F. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169, 1543–1555 (1989).

    Article  CAS  PubMed  Google Scholar 

  88. Marigo, I. et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30, 651 (2016).

    Article  CAS  PubMed  Google Scholar 

  89. Albina, J. E., Mills, C. D., Henry, W. L. Jr. & Caldwell, M. D. Temporal expression of different pathways of 1-arginine metabolism in healing wounds. J. Immunol. 144, 3877–3880 (1990).

    CAS  PubMed  Google Scholar 

  90. Chang, C. I., Liao, J. C. & Kuo, L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 61, 1100–1106 (2001).

    CAS  PubMed  Google Scholar 

  91. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Rodriguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180–191 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839–5849 (2004).

    Article  CAS  PubMed  Google Scholar 

  94. Zea, A. H. et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044–3048 (2005).

    Article  CAS  PubMed  Google Scholar 

  95. Geiger, R. et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829–842 (2016). e13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Ferns, D. M. et al. Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. Oncoimmunology 4, e981457 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Liu, H. et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci. Rep. 6, 21319 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Choe, J. Y. et al. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer 14, 335 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Munn, D. H. & Mellor, A. L. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 37, 193–207 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633–642 (2005).

    Article  CAS  PubMed  Google Scholar 

  101. Van de Velde, L. A., Gingras, S., Pelletier, S. & Murray, P. J. Issues with the specificity of immunological reagents for murine IDO1. Cell Metab. 23, 389–390 (2016).

    Article  PubMed  CAS  Google Scholar 

  102. Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447–457 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Zaher, S. S., Germain, C., Fu, H., Larkin, D. F. & George, A. J. 3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 52, 2640–2648 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).

    Article  CAS  PubMed  Google Scholar 

  105. Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280–290 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Sharma, M. D. et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 2570–2582 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Holmgaard, R. B. et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13, 412–424 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Yu, J. et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190, 3783–3797 (2013).

    Article  CAS  PubMed  Google Scholar 

  109. Schafer, C. C. et al. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget 7, 75407–75424 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  110. Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P. & Kalinski, P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118, 5498–5505 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Jitschin, R. et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 124, 750–760 (2014).

    Article  CAS  PubMed  Google Scholar 

  112. Yu, J. et al. Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol. 193, 2574–2586 (2014).

    Article  CAS  PubMed  Google Scholar 

  113. Smith, C. et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2, 722–735 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Liu, H. et al. GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol. Cell. Biol. 34, 428–438 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Wise, D. R. & Thompson, C. B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427–433 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Mazurek, S. & Eigenbrodt, E. The tumor metabolome. Anticancer Res. 23, 1149–1154 (2003).

    CAS  PubMed  Google Scholar 

  117. Mates, J. M., Perez-Gomez, C., Nunez de Castro, I., Asenjo, M. & Marquez, J. Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. Int. J. Biochem. Cell. Biol. 34, 439–458 (2002).

    Article  CAS  PubMed  Google Scholar 

  118. Droge, W., Eck, H. P., Betzler, M. & Naher, H. Elevated plasma glutamate levels in colorectal carcinoma patients and in patients with acquired immunodeficiency syndrome (AIDS). Immunobiology 174, 473–479 (1987).

    Article  CAS  PubMed  Google Scholar 

  119. Gregory M. A. et al. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp. Hematol. 58, 52–58 (2017).

    Article  CAS  PubMed  Google Scholar 

  120. Emadi, A. et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp. Hematol. 42, 247–251 (2014).

    Article  CAS  PubMed  Google Scholar 

  121. Jacque, N. et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 126, 1346–1356 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the National Institutes of Health (NIH) R01CA184185 to P.C.R.

Author information

Authors and Affiliations

  1. H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. MRC-Annex 2nd, Tampa, FL, 33612, USA

    Eslam Mohamed & Paulo C. Rodriguez

  2. Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA

    Amir A. Al-Khami

Authors
  1. Eslam Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir A. Al-Khami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paulo C. Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paulo C. Rodriguez.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohamed, E., Al-Khami, A.A. & Rodriguez, P.C. The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. Cell Mol Immunol 15, 421–427 (2018). https://doi.org/10.1038/s41423-018-0001-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-018-0001-7

Keywords

This article is cited by

Search

Advanced search

Quick links